Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaka Fadraersada has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The effects of bisphenols on the cardiovascular system ex vivo and in vivo

    by Václav Tvrdý, Patrícia Dias, Iveta Nejmanová, Alejandro Carazo, Eduard Jirkovský, Jana Pourová, Jaka Fadraersada, Monika Moravcová, Lucija Peterlin Mašič, Marija Sollner Dolenc, et al.


  • Open Access

    Can Isoquinoline Alkaloids Affect Platelet Aggregation in Whole Human Blood?

    by Mst Shamima Parvin, Marcel Hrubša, Jaka Fadraersada, Alejandro Carazo, Jana Karlíčková, Lucie Cahlíková, Jakub Chlebek, Kateřina Macáková, Přemysl Mladěnka

    Isoquinoline alkaloids have multiple biological activities, which might be associated with positive pharmacological effects as well as negative adverse reactions. As bleeding was suggested to be a side effect of the isoquinoline alkaloid berberine, we decided to ascertain if different isoquinoline alkaloids could influence hemocoagulation through the inhibition of either platelet aggregation or blood coagulation. Initially, a total of 14 compounds were screened for antiplatelet activity in whole human blood by impedance aggregometry. Eight of them demonstrated an antiplatelet effect against arachidonic acid-induced aggregation. Papaverine and bulbocapnine were the most potent compounds with biologically relevant IC50 values of 26.9 ± 12.2 μM and 30.7 ± 5.4 μM, respectively. Further testing with the same approach confirmed their antiplatelet effects by employing the most physiologically relevant inducer of platelet aggregation, collagen, and demonstrated that bulbocapnine acted at the level of thromboxane receptors. None of the alkaloids tested had an effect on blood coagulation measured by a mechanical coagulometer. In conclusion, the observed antiplatelet effects of isoquinoline alkaloids were found mostly at quite high concentrations, which means that their clinical impact is most likely low. Bulbocapnine was an exception. It proved to be a promising antiplatelet molecule, which may have biologically relevant effects.


  • Open Access

    Comparison of Antiplatelet Effects of Phenol Derivatives in Humans

    by Marcel Hrubša, Raúl Alva, Mst Shamima Parvin, Kateřina Macáková, Jana Karlíčková, Jaka Fadraersada, Lukáš Konečný, Monika Moravcová, Alejandro Carazo, Přemysl Mladěnka

    Flavonoids are associated with positive cardiovascular effects. However, due to their low bioavailability, metabolites are likely responsible for these properties. Recently, one of these metabolites, 4-methylcatechol, was described to be a very potent antiplatelet compound. This study aimed to compare its activity with its 22 close derivatives both of natural or synthetic origin in order to elucidate a potential structure–antiplatelet activity relationship. Blood from human volunteers was induced to aggregate by arachidonic acid (AA), collagen or thrombin, and plasma coagulation was also studied. Potential toxicity was tested on human erythrocytes as well as on a cancer cell line. Our results indicated that 17 out of the 22 compounds were very active at a concentration of 40 μM and, importantly, seven of them had an IC50 on AA-triggered aggregation below 3 μM. The effects of the most active compounds were confirmed on collagen-triggered aggregation too. None of the tested compounds was toxic toward erythrocytes at 50 μM and four compounds partly inhibited proliferation of breast cancer cell line at 100 μM but not at 10 μM. Additionally, none of the compounds had a significant effect on blood coagulation or thrombin-triggered aggregation. This study hence reports four phenol derivatives (4-ethylcatechol, 4-fluorocatechol, 2-methoxy-4-ethylphenol and 3-methylcatechol) suitable for future in vivo testing.